BrickBio, a company specializing in site-specific bioconjugation for improved therapeutics, has signed an agreement with a large pharmaceutical company to co-develop a therapeutic antibody drug conjugate (ADC). Additional details were not disclosed.   BrickBio focuses in the areas of oncology, neurology, and metabolic disease, although the company’s site-specific modification process is expandable beyond the scope of these disease areas. In addition to expanding its internal pipeline, th...